← Briefing history

The financial reality of major US health insurers has decoupled from the public narrative of underwriting profits, as heavily regulated…

Read-only snapshot of How Health Insurers Actually Make Money

Aug 3, 2026 · 6 findings · closed 1 thread · ran 14m 45s

TL;DR

The financial reality of major US health insurers has decoupled from the public narrative of underwriting profits, as heavily regulated insurance margins are squeezed to near-zero or negative levels. Enterprise profitability is now sustained by routing patient volume through high-margin, unregulated vertical services, clinical networks, and specialty pharmacies. While state regulators are launching aggressive legislative campaigns to break up these integrated empires, federal courts remain a formidable shield for the industry's economic model.

The Great Margin Shift to Unregulated Vertical Services

Underwriting margins in government-sponsored health plans are collapsing under regulatory and demographic pressures, forcing conglomerates to rely on their unregulated clinical and specialty services to drive profitability.

"We continue to see 2026 as the trough year for our Medicaid margin, with improvement over time supported by better rate alignment and the maturation of our care management actions..."Elevance Health: Carelon and the Internal Profit Enginehcinnovationgroup.cominsurancenewsnet.comhealthcaredive.comstocktitan.net

"As we see stronger adoption of biosimilars and specialty generics, it’s a benefit for us overall in Evernorth from a margin perspective... lower results in Pharmacy Benefit Services and higher results in Specialty and Care Services is sort of how it all comes together."Cigna's Pivot to Evernorth and the De-Risked Commercial Employer Focusqz.comforbes.compublic-markets-api.com

This shift demonstrates that the traditional insurance business is increasingly becoming a low-margin pass-through. While Elevance projects a sicker-than-expected full-year Medicaid operating margin of approximately -1.75% Elevance Health: Carelon and the Internal Profit Enginehcinnovationgroup.cominsurancenewsnet.comhealthcaredive.comstocktitan.net, its internal services arm, Carelon, successfully offsets this drag. Similarly, Cigna is actively shifting earnings from traditional pharmacy benefit manager (PBM) rebate models to its high-margin specialty pharmacy, Accredo, which generated $1.054 billion in pre-tax adjusted operating earnings Cigna's Pivot to Evernorth and the De-Risked Commercial Employer Focusqz.comforbes.compublic-markets-api.com. By capturing multiple margin points across internal delivery chains, health giants insulate their consolidated earnings from government rate cuts.

What to watch: Watch for whether other major insurers follow Cigna's lead in narrowing their exposure to volatile government risk Cigna's Pivot to Evernorth and the De-Risked Commercial Employer Focusqz.comforbes.compublic-markets-api.com to focus almost exclusively on commercial plans and specialty services.

State-Level Regulatory Warfare and the ERISA Shield

States are launching aggressive legislative campaigns to dismantle integrated pharmacy benefit manager structures, triggering a high-stakes legal defense centered on federal preemption.

"...the practical effect of the law was to 'requir[e] PBMs to tailor and retailor their networks — and perhaps even build new brick-and-mortar pharmacies — to comply with a set of exacting particularities...'"PBM Vertical Integration: State Ownership Restrictions and the Tennessee Strategic Rewritelaw.justia.comtnpharm.orgbipc.commintz.com

This legal battleground highlights the tension between local policymakers trying to protect community pharmacies and conglomerates defending their integrated supply chains. In Flowers v. Caremark PCS Health, the Eighth Circuit Court of Appeals ruled that ERISA preempts state geographic network requirements, establishing a powerful precedent against local overreach PBM Vertical Integration: State Ownership Restrictions and the Tennessee Strategic Rewritelaw.justia.comtnpharm.orgbipc.commintz.com. However, the fight has escalated with Tennessee's FAIR Rx Act, which attempts to bypass federal preemption to force PBMs to divest their owned pharmacies by January 1, 2027 PBM Vertical Integration: State Ownership Restrictions and the Tennessee Strategic Rewritelaw.justia.comtnpharm.orgbipc.commintz.com.

What to watch: Watch for the federal court's ruling on the consolidated Tennessee FAIR Rx Act litigation [PBM Vertical Integration: State Ownership Restrictions and the Tennessee Strategic Rewrite](/topics/019e89d0-893e-7d00-a5cf-ca1051e66e9d/notes/pbm-vertical-integration-state-ownership-restrictions], which will test whether states can constitutionally force the breakup of vertically integrated healthcare giants.

What surprised us

Open threads worth a vote

Findings from this cycle

Current topic brief

Shown for context; the brief may have changed since this cycle ran.

Adjudicate how US health insurers actually earn their profits — the gap between "they're hated" and a clear-eyed read of the economics. Stay analytical and grounded in the filings. Core entities: the large managed-care companies (UnitedHealth/Optum, Elevance, Cigna, CVS/Aetna, Humana, Centene) and the profit centers inside them (the medical-loss ratio and where the regulated margin sits, the PBM leg, Medicare Advantage, Optum-style vertical integration). I want to track these companies' filings and earnings for MLR, MA enrollment and rates, PBM economics, and segment margins; CMS rate notices and MA policy; any DOJ/FTC action on PBMs or vertical integration; and the recurring controversies (denials, prior authorization) against what the numbers show. Pull prices, filings, and earnings-call quotes for the named insurers. Separate where the profit actually comes from (often Optum/PBM, not the regulated insurance margin) from the popular narrative, and weigh policy-risk claims on the evidence. Flag regulatory moves that threaten a specific profit center, and any divergence between the public narrative and the segment economics. The thesis: the anger is real but the economics are widely misunderstood — explain where the money actually is.